On March 4, Boji Medical Technology Co.Ltd(300404) and Wuhan Yicheng biology held the signing ceremony of phase III clinical trial cooperation of “epiutide nasal drops”, marking that class I new drug “epiutide nasal drops” is about to enter the phase III clinical research stage.
Ipiuptide is a specific inhibitor of p55PIK, a member of PI3K subtype, developed by Wuhan Yicheng Biotechnology Co., Ltd. It can treat inflammatory diseases through a variety of effector mechanisms: (1) inhibit inflammation and participate in cell proliferation; (2) Inhibit NF, which plays an important role in the inflammatory process- κ B activates the signal transduction mechanism and inhibits the production and secretion of inflammatory mediators; (3) Regulate the inflammatory process and slow down the aggregation and invasion of inflammatory cells; (4) Inhibit angiogenesis at the inflamed site.
At present, the research and development of iputide in the treatment of allergic rhinitis has completed the phase II clinical trial, and the phase III clinical trial is planned to be carried out. The results of phase I clinical trial showed that it was well tolerated and safe. The results of phase II clinical trial showed that iputide was better than placebo in some efficacy indexes. The listing of iputide will give patients with allergic rhinitis more choices. Because there is no drug with the same action mechanism on the market, iputide has a broad market prospect. (Li Wuqiang)
